Market cap
₹446 Cr
Recently Viewed
Clear AllNSE: SMSLIFE | BSE: 540679
₹1,456.80
₹-44.00
(-2.93%)
As on 30-Apr-2026IST
Market cap
₹446 Cr
Revenue (TTM)
₹348 Cr
P/E Ratio
22.5
P/B Ratio
2.1
Div. Yield
0.1 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹20 Cr
ROE
10 %
ROCE
12.6 %
Industry P/E
36.61
EV/EBITDA
10.1
Debt to Equity
0.4
Book Value
₹704.8
EPS
₹65.7
Face value
10
Shares outstanding
3,023,287
CFO
₹169.18 Cr
EBITDA
₹271.79 Cr
Net Profit
₹122.77 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SMS Lifesciences
| 10.0 | 17.2 | 29.3 | 9.9 | 38.8 | 19.2 | -- |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
SMS Lifesciences
| 10.4 | 122.7 | -15.3 | -14.5 | 18.3 | 147.1 | -45.7 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
SMS Lifesciences
|
1,456.8 | 445.9 | 347.8 | 20.9 | 9.0 | 9.9 | 22.5 | 2.1 |
| 1,038.2 | 12,733.9 | 2,512.3 | 543.7 | 28.3 | 19.3 | 23.4 | 4.0 | |
| 444.6 | 7,694.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 26.2 | 5.9 | |
| 1,142.0 | 11,927.8 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,680.1 | 31,850.1 | 8,850.1 | 894.8 | 15.2 | 19.8 | 36.6 | 6.4 | |
| 363.6 | 3,963.6 | 159.3 | 47.8 | 39.0 | 18.6 | 82.9 | 14.3 | |
| 15,003.0 | 19,243.2 | 1,575.1 | 179.1 | 14.9 | 11.4 | 107.4 | 11.6 | |
| 899.2 | 4,138.8 | 588.5 | 102.9 | 22.1 | 12.7 | 40.7 | 4.9 | |
| 707.6 | 7,997.9 | 502.0 | 138.7 | -- | 32.8 | 57.7 | 9.2 | |
| 211.9 | 5,585.6 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.4 |
No Review & Analysis are available.
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction,... anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India. Read more
Incorporated
2006
Chairman
--
Managing Director
TVVSN Murthy
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsEncumbrance (Annual Disclosure)
08-Apr-2026Annual Confirmation (Reclassification)
08-Apr-2026Events Calendar (Postal Ballot)
26-Mar-2026Special Window (Physical Shares)
28-Feb-2026Newspaper Publication (Financial Results)
13-Feb-2026No News & Announcements are available.
The share price of SMS Lifesciences India Ltd is ₹1,456.80 (NSE) and ₹1,474.90 (BSE) as of 30-Apr-2026 IST. SMS Lifesciences India Ltd has given a return of 38.85% in the last 3 years.
The P/E ratio of SMS Lifesciences India Ltd is 22.46 times as on 30-Apr-2026, a 39 discount to its peers’ median range of 36.61 times.
The P/B ratio of SMS Lifesciences India Ltd is 2.09 times as on 30-Apr-2026, a 13 discount to its peers’ median range of 2.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.24
|
1.66
|
|
2024
|
22.57
|
1.16
|
|
2023
|
13.71
|
0.93
|
|
2022
|
8.30
|
1.38
|
|
2021
|
11.04
|
1.16
|
The 52-week high and low of SMS Lifesciences India Ltd are Rs 1,559.90 and Rs 1,067.00 as of 01-May-2026.
SMS Lifesciences India Ltd has a market capitalisation of ₹ 446 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in SMS Lifesciences India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.